Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

603087 Gan&Lee Pharmaceuticals.

Closed 04-24 15:00:00

60.41

+0.93

+1.56%

High60.84	Low58.83	Vol8.73M
Open59.25	D1 Closing59.48	Amplitude3.38%
Mkt Cap36.06B	Tradable Cap33.71B	Total Shares597.00M
T/O524.00M	T/O Rate1.56%	Tradable Shares558.00M
P/B3.05	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"Gan&Lee Pharmaceuticals.","latestPrice":60.41,"timestamp":1777014000000,"preClose":59.48,"halted":0,"volume":8727393,"delay":0,"changeRate":0.0156,"floatShares":558000000,"shares":597000000,"eps":1.7147,"marketStatus":"Closed","change":0.93,"latestTime":"04-24 15:00:00","open":59.25,"high":60.84,"low":58.83,"amount":524000000,"amplitude":0.0338,"askPrice":60.42,"askSize":210,"bidPrice":60.41,"bidSize":204,"shortable":0,"etf":0,"ttmEps":1.7147,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":59.48,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":65.43,"lowLimit":53.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.05,"roa":"--","peRate":35.230653,"roe":"1.64%","epsLYR":1.93,"committee":-0.096774,"marketValue":36083000000,"turnoverRate":0.0156,"status":0,"floatMarketCap":33700000000},"requestUrl":"/m/hq/s/603087/wiki","defaultTab":"wiki","newsList":[{"id":"2629001561","title":"BUZZ-China's Gan & Lee Pharmaceuticals heads for biggest drop in a year on lower Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001561","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629001561?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:16","pubTimestamp":1776921381,"startTime":"0","endTime":"0","summary":"BUZZ-China's Gan & Lee Pharmaceuticals heads for biggest drop in a year on lower Q1 results   ** Shares of Gan & Lee Pharmaceuticals 603087.SS drop 8.8% to 59.9 yuan, on track for biggest one-day pct decline since April 7, 2025** Stock hits the lowest level since March 27** China-based insulin analogue active pharmaceutical ingredients and injectable formulations producer said its Q1 net profit plunged 38.3% y/y with revenue down 10.8% y/y** YTD, stock down 12%, benchmark CSI300 Index .CSI300 up 2.9%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL1N41606K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017531","title":"BRIEF-Gan & Lee Pharmaceuticals 2025 Net Profit Up 86.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017531","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017531?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:28","pubTimestamp":1776853686,"startTime":"0","endTime":"0","summary":"BRIEF-Gan & Lee Pharmaceuticals 2025 Net Profit Up 86.1% Y/YApril 22 (Reuters) - Gan & Lee Pharmaceuticals 603087.SS:2025 NET PROFIT UP 86.1% Y/YSource textFurther company coverage: 603087.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4N4150YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627226679","title":"Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2627226679","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627226679?lang=en_us&edition=fundamental","pubTime":"2026-04-16 13:34","pubTimestamp":1776317640,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested for the treatment of neovascular  age-related macular degeneration in adults.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406836","title":"Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406836","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627406836?lang=en_us&edition=fundamental","pubTime":"2026-04-15 14:49","pubTimestamp":1776235795,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals'  subsidiary, Gan & Lee Pharmaceuticals Shandong, dosed the first subject for the phase III clinical trial of GZR33 injection, according to a Shanghai bourse filing on Wednesday.The drug is being tested as a treatment for type 2 diabetes.The pharmaceutical company's shares rose less than 3% during the afternoon trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4134","603087","III","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626808251","title":"BRIEF-Gan & Lee Pharmaceuticals - Signs Exclusive License Agreement With Jw Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2626808251","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626808251?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:13","pubTimestamp":1775740428,"startTime":"0","endTime":"0","summary":"BRIEF-Gan & Lee Pharmaceuticals - Signs Exclusive License Agreement With Jw PharmaceuticalApril 9 (Reuters) - Gan & Lee Pharmaceuticals 603087.SS:GAN & LEE PHARMACEUTICALS - SIGNS EXCLUSIVE LICENSE AG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626187061","title":"Gan & Lee Pharmaceuticals - Parties to Collaborate, Others on Clinical Development in South Korea of Bofanglutide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2626187061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626187061?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:10","pubTimestamp":1775740213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0DB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625992981","title":"Gan & Lee Pharmaceuticals Gets Regulatory Approval for Diabetes Combo Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625992981","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625992981?lang=en_us&edition=fundamental","pubTime":"2026-04-08 13:22","pubTimestamp":1775625779,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  obtained registration from China's drug regulator for sitagliptin and metformin hydrochloride tablets.The drug is a fixed-dose combination for type 2 diabetes, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625982405","title":"Gan & Lee Pharmaceuticals Doses First Patient in Prostate Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625982405","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625982405?lang=en_us&edition=fundamental","pubTime":"2026-04-07 14:13","pubTimestamp":1775542413,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  said the first subject has been dosed in a Phase I clinical trial for its investigational drug, GLR2037 tablets, according to a Saturday filing on the Shanghai bourse.The Chinese pharmaceutical company's shares slipped less than 1% during Tuesday's afternoon trade.The drug is being tested as a treatment for advanced prostate cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136390392","title":"Gan & Lee Pharmaceuticals Advances GLR2037 Tablet to Phase I Clinical Trial Stage with First Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=1136390392","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136390392?lang=en_us&edition=fundamental","pubTime":"2026-04-03 15:44","pubTimestamp":1775202254,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (603087.SH) has announced that its self-developed GLR2037 tablet has commenced a Phase I clinical trial in China, with the first participant recently receiving the initial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147801669","title":"Gan & Lee Pharmaceuticals Subsidiary Secures GMP Certification from Brazilian Health Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1147801669","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147801669?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:28","pubTimestamp":1775129313,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) has announced that its subsidiary, Gan & Lee Brazil Trading and Pharmaceutical Import Limited Liability Company, recently obtained a Good Manufacturing Practice...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159100","603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858276","title":"Gan & Lee Pharmaceuticals - Once-Weekly Gzr4 Shows Favorable Safety Profile With No Severe Hypoglycemic Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623858276?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:36","pubTimestamp":1774964212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA82YVRW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623754582","title":"Gan & Lee Pharmaceuticals - Once-Weekly Gzr4 Reduces Annual Injection Frequency by More Than 85% Compared to Once-Daily Insulins","url":"https://stock-news.laohu8.com/highlight/detail?id=2623754582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623754582?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:36","pubTimestamp":1774964212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA82YVRW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623582763","title":"Gan & Lee Pharmaceuticals - Gzr4 Injection Shows Superior Hba1c Reduction Versus Lantus and Tresiba After 26 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2623582763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623582763?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:36","pubTimestamp":1774964212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA82YVRW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623225582","title":"Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin Gzr4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: Super-1 and Super-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2623225582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623225582?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:36","pubTimestamp":1774964212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA82YVRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622350049","title":"Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea","url":"https://stock-news.laohu8.com/highlight/detail?id=2622350049","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622350049?lang=en_us&edition=fundamental","pubTime":"2026-03-25 12:09","pubTimestamp":1774411760,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (SHA:603087) obtained the approval of China's drug regulator to conduct clinical trial approval for bofangglutide (GZR18).The drug is used to treat moderate to severe obstructive sleep apnea in obese adults, according to a Wednesday filing with the Shanghai bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616348506","title":"Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2616348506","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616348506?lang=en_us&edition=fundamental","pubTime":"2026-03-03 17:15","pubTimestamp":1772529331,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  obtained the approval of China's drug regulator to conduct clinical trials for GLR2037 tablets to treat advanced prostate cancer.The investigational therapy utilizes novel protein degradation technology to target androgen receptors, according to a Tuesday filing with the Shanghai bourse.Shares of the company were down 3% Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169160645","title":"Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1169160645","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169160645?lang=en_us&edition=fundamental","pubTime":"2026-03-03 13:21","pubTimestamp":1772515309,"startTime":"0","endTime":"0","summary":"On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121012946","title":"Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1121012946","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121012946?lang=en_us&edition=fundamental","pubTime":"2026-03-02 18:12","pubTimestamp":1772446337,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605745651","title":"Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605745651","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605745651?lang=en_us&edition=fundamental","pubTime":"2026-01-22 11:27","pubTimestamp":1769052468,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  expects its net profit attributable to shareholders in 2025 to jump between 79% and 95% year on year to 1.10 billion yuan and 1.20 billion yuan, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's attributable profit a year earlier was 614.7 million yuan or 1.04 yuan per share.The company's shares slipped nearly 2% during the morning trade Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194687370","title":"Gan & Lee Pharmaceuticals (603087.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Owners to Increase 78.96% to 95.23% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1194687370","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194687370?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:39","pubTimestamp":1768995577,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) has released its 2025 annual performance forecast, anticipating a net profit attributable to owners of the parent company in the range of 1.10 billion to 1.20...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","stockEarnings":[{"period":"1week","weight":-0.0984},{"period":"1month","weight":0.0355},{"period":"3month","weight":-0.1833},{"period":"6month","weight":-0.1358},{"period":"1year","weight":0.3451},{"period":"ytd","weight":-0.1262}],"companyName":"甘李药业股份有限公司","boardCode":"AI0027","perCapita":"6806股","boardName":"医药制造业","registeredCapital":"59730万元","compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0546},{"period":"3month","weight":-0.0104},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2418},{"period":"ytd","weight":0.0313}],"survey":"　　甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","serverTime":1777029084284,"listedPrice":63.32,"stockholders":"81965人(较上一季度减少5.45%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gan&Lee Pharmaceuticals.,603087,Gan&Lee Pharmaceuticals.股票,Gan&Lee Pharmaceuticals.股票老虎,Gan&Lee Pharmaceuticals.股票老虎国际,Gan&Lee Pharmaceuticals.行情,Gan&Lee Pharmaceuticals.股票行情,Gan&Lee Pharmaceuticals.股价,Gan&Lee Pharmaceuticals.股市,Gan&Lee Pharmaceuticals.股票价格,Gan&Lee Pharmaceuticals.股票交易,Gan&Lee Pharmaceuticals.股票购买,Gan&Lee Pharmaceuticals.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction